Brain tumors are the deadliest form of childhood cancer. Although survival rates for some pediatric brain tumors have increased over the past few decades, current treatment options including radiation and chemotherapy are often quite toxic, causing children to often suffer from long-term side effects.
Investigators at Nationwide Children’s Hospital are focused on developing treatment strategies for children with brain tumors that not only treat disease, but ensure improved quality of life.
Virotherapy Shows Promise Against Highly Malignant Pediatric Tumors
Adam Studebaker, PhD, research scientist in the Center for Childhood Cancer and Blood Diseases at The Research Institute at Nationwide Children’s, is lead author of a recent Neuro-Oncology paper that shows a modified measles virus is an effective therapeutic agent against a type of tumor that does not respond well to chemotherapy and primarily affects children under 3 years of age
Head Start 4 Randomized Clinical Trial
The Head Start 4 protocol is a randomized clinical trial hosted and coordinated by Nationwide Children’s NEXT Consortium, with other treatment centers participating around the world. The goals of this study are to determine if the treatment in the protocol will improve the quality of survival and cure rates for young children (age 10 years or less) newly diagnosed with the most common types of malignant brain tumors in childhood, medulloblastoma and other PNETs (primitive neuro-ectodermal tumors). More than 40 institutions throughout the world have agreed to participated in the study including centers in the United States, Canada, Brazil, Australia, the United Kingdom and New Zealand.
Comprehensive Neuro-Oncology Clinic
The Neuro-Oncology Clinic focuses on the needs of children, adolescents and young adults who have been diagnosed with any pediatric cancer of the central nervous system (brain or spinal cord).
Contact the Neuro-Oncology Department at Nationwide Children's.